Date: 30/01/2025

*** GENERAL ADVICE ONLY***

Telix Pharmaceuticals: A Rising Star in Radiopharmaceuticals Expands Its Reach

Telix Pharmaceuticals (ASX: TLX, Nasdaq: TLX) has taken a significant leap forward in its mission to become a leader in radiopharmaceuticals with the completion of its acquisition of RLS (USA) Inc. (RLS Radiopharmacies) on January 28, 2025.

This strategic move marks a pivotal moment in Telix’s growth trajectory, enhancing its presence in the United States and bolstering its capabilities in the development and commercialization of radiopharmaceuticals for cancer treatment and diagnosis.

Acquisition Details

Telix has acquired 100% ownership of RLS for an upfront cash consideration of US$230 million, with potential additional deferred payments of up to US$20 million based on performance milestones3. This acquisition brings America’s only Joint Commission-accredited radiopharmacy network under Telix’s umbrella, significantly expanding its distribution capabilities with over 30 radiopharmacies across major metropolitan areas in the U.S.

Strategic Implications

The integration of RLS into Telix’s operations is set to create an enhanced radiopharmaceutical ecosystem:

1. Expanded U.S. Presence: The acquisition immediately strengthens Telix’s footprint in its largest market, the United States.
2. Advanced Distribution Network: With over 30 radiopharmacies, Telix can now more effectively distribute its own products and those of other companies2.
3. Increased Production Capacity: RLS brings over 100,000 square feet of licensed expansion space, enabling Telix to build a next-generation radiometal production network.
4. Skilled Workforce: The acquisition brings a team of highly-skilled radiopharmaceutical professionals into Telix.
5. Technological Integration: Telix plans to deploy its ARTMS QUANTM Irradiation System™ (QIS™) cyclotron technology across the RLS network, enhancing production efficiency.

Future Prospects

This acquisition aligns with Telix’s strategy to establish an integrated radiopharmaceutical ecosystem, enhancing its ability to deliver novel therapeutic and diagnostic radiopharmaceuticals to patients3. Dr. Christian Behrenbruch, Telix’s Managing Director and Group CEO, emphasized that this move positions Telix to bring its growing portfolio of innovative products to more patients across the U.S. RLS will continue to operate under its own name as a standalone business within Telix Manufacturing Solutions (TMS), alongside other key Telix brands such as ARTMS, IsoTherapeutics, and Optimal Tracers3. This structure allows Telix to maintain RLS’s existing customer relationships while leveraging synergies across its expanded operations.

As Telix continues to innovate and expand its product portfolio, including its lead prostate imaging product Illuccix® and other pipeline products, this acquisition provides a robust platform for growth. With its strengthened commercial infrastructure and distribution capabilities, Telix is well-positioned to address significant unmet medical needs in oncology and rare diseases, solidifying its status as a rising star in the radiopharmaceutical industry.